

# **The Tale of a Bacteria Battle**

A study on *Staphylococcus aureus*, its prevalence, possible clinical symptoms and the tools we have available to fight it

KFL082

3932 words



# Contents

|          |   |            |
|----------|---|------------|
| <b>1</b> | <b>Introduction</b>   | <b>3</b>   |
| <b>2</b> | <b>Theoretical context</b>  | <b>5</b>   |
| 2.1      | Bacteria and bacterial infections . . . . .                         | 5          |
| 2.2      | The enemy: <i>Staphylococcus aureus</i> . . . . .                   | 6          |
| 2.3      | The enemy's attacks . . . . .                                       | 7          |
| 2.4      | Our weapons . . . . .   | 8          |
| <b>3</b> | <b>Experimental design</b>  | <b>13</b>  |
| 3.1      | Variables studied . . . . .   | 14         |
| 3.2      | Bill of materials . . . . .   | 14         |
| 3.3      | Biosecurity and risk mitigation . . . . .                           | 15         |
| 3.4      | Protocol followed . . . . .   | 15         |
| <b>4</b> | <b>Physical experimentation</b>                                     | <b>19</b>  |
| 4.1      | Description . . . . .   | 19         |
| 4.2      | Results and analysis . . . . .                                      | 21         |
| <b>5</b> | <b>Conclusions</b>  | <b>25</b>  |
| 5.1      | Bibliographic conclusions . . . . .                                 | 25         |
| 5.2      | Experimental conclusions . . . . .                                  | 25         |
| 5.3      | Strengths and weaknesses . . . . .                                  | 26         |
| 5.4      | Possible improvements . . . . .                                     | 27         |
| <b>I</b> | <b>Appendix</b>   | <b>III</b> |
|          | <b>Annex 1 – Informed consent given to subjects before sampling</b> | <b>V</b>   |
|          | <b>Annex 2 – GDPR notice given to subjects before sampling</b>      | <b>XI</b>  |

**Annex 3 – Bibliography consulted (but not referenced)****XV**

# 1

# Introduction

Good writing starts strong. Not with a cliché, not with a banality, but with a contentful observation that provokes curiosity.

---

Stephen King

A few years ago, in summer of 2021, I was accepted into a program at the Barcelona Autonomous University, aimed to divulge microbiology and biotechnology to a group of 50 biology-loving students. That's where I learned bacteria in detail, as well as how a microbiology/biotechnology lab functions. I fell in love with the discipline at first sight. I wondered how research in this field works. I took one of the experiments we did, and decide to expand it for my EE.

This extended essay has as primary objective answering these two questions:

"*What is the prevalence of Staphylococcus aureus in our school?*"

"*Is the prevalence of Staphylococcus aureus affected by gender or age?*"

And its secondary ones include studying bibliographically *Staphylococcus aureus*, improving my lab etiquette and protocol-making, and allowing me to practice microbiology techniques.

This study required taking samples from human subjects. The results were, when available, communicated to the subjects via e-mail. They were informed previously on the process they would go through, as well as the purpose of the experiment. Each subject had to read and agree to two documents: an informed consent which explains everything about the experiment<sup>1</sup>, and a GDPR notice which documents the use

---

<sup>1</sup>See annex 1

---

of their data as well as an expected timeline for its destruction[1]<sup>2</sup>. The experimentation followed lead to no effect on the subjects.

Since bacteria were used, some aspects of the experiment had to be clarified and discussed. Previously to starting to design the protocol, I read the WHO's Laboratory Biosafety Manual and Associated Monographs (4Th Edition)[2], to mitigate or eliminate any possible risk. During the experimental phases, there were no incidents. All plates were accounted for. No person other than me was allowed to come in contact with any of the Petri dishes, nor with any used but not yet disinfected auxiliary material. The cultivated plates were considered Biosecurity Level 2. All possibly infected material was disinfected following the WHO recommendations. Following the IBO EE guidelines, I talked with my coordinator in order to solidify the fact that there was no alternative to sampling from humans, as well as to consider the risks that this experiment implied because of bacteria.

---

<sup>2</sup>See annex 2

# 2 Theoretical context

Each source that I read, I would look through the bibliography and the footnotes, and use that as a map for the next thing I would read.

---

Alexander Chee

## §2.1 Bacteria and bacterial infections

**Bacteria** are prokaryotic organisms, generally single-celled, which are part of the Monera kingdom. Their sizes range from between  $30\mu\text{m}$  and  $100\mu\text{m}$  and are ubiquitous<sup>1</sup> organisms. This form of life is believed to be the first one to have ever appeared on Earth, as well as the one responsible for the oxygen-rich atmosphere the Earth currently has. Some species are hard to culture in a laboratory environment, but generally, those that can be cultured in a controlled environment are grown in agar plates[3].

**Pathogenic bacteria** are bacteria that have the ability to cause disease<sup>2</sup>. These are not the most common type of bacteria, as the majority of them are either harmless or beneficial to the human body through symbiosis, such as the bacteria that help with digestion in the stomach[3].

---

<sup>1</sup>Ubiquitous: found everywhere

<sup>2</sup>A disease is a particular abnormal condition that negatively affects the structure or function of all or part of an organism, and that is not immediately due to any external injury[4].

## §2.2 The enemy: *Staphylococcus aureus*

*Staphylococcus aureus* (also known as Staph) is a GRAM-positive bacterium, usually not pathogenic. It can, in some cases, cause extremely dangerous infections. Some of its distinctive characteristics include a very thick glycopeptide wall, which allows it to withstand extreme temperatures and osmotic pressures, rendering most classic methods of food conservation<sup>3</sup> useless against it; a protein A capsid, which binds to most eukaryote cells; as well as thermostable enterotoxins. It's a bacterium that can resist many environments, and can be found on human skin, mucous surfaces, as well as in certain foods such as ham, eggs, and poultry[5].

---

<sup>3</sup>Cooking, smoking, freezing, salting...

*Staphylococcus aureus* has three main parts to its virulence: its cell wall, its membrane-bound factors and its secreted factors. Staph's cell wall is made up of three parts. From the inside out they are: a plasma membrane, a peptidoglycan layer and a capsule[6]. The membrane includes a semipermeable lipid bi-layer, which regulates the transport of materials entering and exiting the cell. Integrated inside it are a type of integral protein called penicillin-binding protein (PBP), along with proteins dedicated to powered transport. We are only interested in PBPs. Even though the name implies PBPs are only sensible to penicillin, the name actually came to be this way because of their discovery. These proteins are sensitive to the  $\beta$ -lactam groups in antibiotics. Variations in them may lead to antibiotic-resistant strains, such as MRSA (*Methicillin-Resistant Staphylococcus aureus*), result of a mutation in this protein called PBPA2[7]. *Staphylococcus aureus*, like all other members of the *Staphylococcus* family, has a very thick peptidoglycan layer. This grants them protection from extreme temperatures and high osmotic pressures. Since little to no other bacteria can survive in the conditions that Staph can, it starts reproducing without the limit that would be imposed by having other bacteria competing for the same resources[8].




Figure 2.1: Parts of *Staphylococcus aureus*[6].

### §2.3 The enemy's attacks

*Staphylococcus aureus* is a species that can cause a handful of different diseases, ranging from, most frequently, skin and respiratory tract infections to infective endocarditis, toxic shock syndrome or osteomyelitis[9]. Several variations of this pathogen exist, with increasing levels of antibiotic resistance: MSSA (*Methicillin-Sensitive Staphylococcus aureus*), having no resistance; MRSA (*Methicillin-Resistant Staphylococcus aureus*); and VRSA (*Vancomycin-Resistant Staphylococcus aureus*), the latter for which no antibiotic

concoction that can eradicate the infection is known, and the patients have to use experimental treatments. VISA (*Vancomycin-intermediate Staphylococcus aureus*) is a variation that has medium resistance to vancomycin, being an intermediate step between MRSA and VRSA. Studies have discovered that this genetic factor has been developed by different lineages separately, indicating that there is not a common ancestor of MRSA strains[10].

*Staphylococcus aureus* contains an important quantity of **toxins**, compounds that grant *Staph* most of its pathogenicity. Many of its virulence factors can be described as such. Toxins are usually defined as poisonous substances, which, in our case, means that they have the capacity to mess with the host body directly, without need of a mediating entity. *Staph* has several kinds of toxin in its arsenal: membrane-damaging toxins (which can be receptor-mediated or not), receptor-interfering toxins (which do not damage the membrane), enzymes, and pathway blockers[7].

## §2.4 Our weapons

The tools we have at our disposal to fight off this infection fall into two main categories: chemical factors and biological factors.

The chemical factors are drugs, and they depend both in quantity and type on the variation a particular case falls in. It is **extremely important** to find out the level of antibiotic resistance that a specific infection has before administering any antibiotic, as this treatment course will cause side effects such as killing gut bacteria, diminishing defence system capabilities, and increasing the possibility to develop yet more resistant infections. Generally, a large-spectrum antibiotic has an adequate risk-to-benefits ratio of causing the previously mentioned side effects, so they may be used before switching to a more specific (and in some cases even more violent) treatment.

Starting with the treatment to the least resistant strains of *Staphylococcus aureus*, a  $\beta$ -lactam antibiotic (such as methicillin, oxacillin, cloxacillin and penicillin) is the weapon of choice to fight against an MSSA infection. This is because this specific chemical part (just a  $\beta$ -lactam ring does nothing by itself) has the ability to inhibit cell wall biosynthesis on the bacterial intruder's body. But once the  $\beta$ -lactam ring is cut by an enzyme secreted by the bacteria itself, this type of antibiotic suddenly loses effect against them.

That's where vancomycin comes in. It is a type of glycopeptide antibiotic, just like  $\beta$ -lactam, and works by blocking the construction of a cell wall, as all of its type do. This treatment is very invasive and only indicated for the treatment of extremely serious, life-threatening infections by Gram-positive bacteria that have shown to be unresponsive to other antibiotics. It can be taken as a pill or as an injectable fluid, the latter form proving to be much more effective than the former. This treatment is incompatible with aminoglycosides, a type of antibiotic that inhibits protein synthesis, as it can lead to nephrotoxicity and ototoxicity. Vancomycin can induce internal bleeding, with petechial haemorrhages on the tongue and bruises on most of the body of the patient. Unfortunately, even with use of vancomycin, *Staphylococcus aureus* can develop resistance. In this case, no other option than using a biological factor is left.




Figure 2.2: Organic chemistry structure of penicillin (top) and cephalexin (bottom). The  $\beta$ -lactam ring is indicated in red.  
Source: [11]




Figure 2.3: Organic chemistry structure of vancomycin. Source: [12]

may be available soon.[10][13].

The biological factor is a bacteriophage, called P68. It comes from the *Caudovirales* order, which means that it is a bacteriophage with tail. This treatment is still in testing, but it appears to be effective and lead to low adverse results. If possible, it would be preferable to use bacteriophage therapy (shortened to phage therapy) instead of going for antibiotics, as it can lead to less side effects than antibiotics, as it only attacks a specific bacterium. This means that the infection has to be pinpointed with extreme accuracy. The use of this treatment also negates the risk of bacteria developing antibiotic resistance. It is, however, unclear whether the bacteriophage could mutate into a dangerous strain. This therapy is in clinical research, and

Bacteriophages work in an interesting manner. They work by detecting one very specific bacteria, just like any other virus does with the type of cell they evolved for, then bind to it and inject their genetic material, which then in turn the bacteria considers as its own, inserts it into its own genetic sequence and starts producing the proteins the virus requires, but it doesn't eject them. Once the bacteria is full of phages, a special lytic compound is released which bursts the cell membrane in such a way that it resembles an explosion, but instead of heating up everything in a radius, spreads millions more of bacteriophages, which then bind to other bacteria and the cycle repeats until there's no more bacteria left. The fight from the bacteria point of view consists mostly on trying to outnumber and outreproduce the phages in order to have a chance of survival, even if minimal. There is no known bacteria that shows resistance to phages. That is probably because, unlike the chemical factors, phages can evolve and improve with each generation thanks to natural selection[[14](#)].




Figure 2.4: External structure of P-68, graphed using AlphaFold. Own source.



# 3 Experimental design

It is common sense to take a method and try it; if it fails, admit it frankly and try another. But above all, try something.

---

*Anthony Burgess*

This Extended Essay has the objective of studying bibliographically the effects of *Staphylococcus aureus* on the human body, as well as the ways humanity has developed to defeat it. Experimentally, it has one main objective, and several secondary ones: answering the research questions posed in the most reliable way I can achieve. Secondly, I want to improve my lab etiquette and fluidity, protocol-making, how I follow protocols in the lab and how I deal with problems that may arise from them, my staining and microscope use, and how I work with limited resources.

The research question I will follow is

*"What is the prevalence of Staphylococcus aureus in our school?"*

To which my hypothesis is:

*"About 30%"*

This hypothesis stems from results I found in a paper published in *The Journal of Infectious Diseases*[15]. I would also like to know the answer to the question

*"Is the prevalence of Staphylococcus aureus affected by gender or age?"*

to which my hypothesis, based on the knowledge of how bacteria colonise, is

“No“

The variable I will study is the presence or not of the bacterium in question on different subjects, and compare it against their characteristics (such as approximate age and gender). I'll keep as control variables the culture medium, the culture temperature and humidity, as well as the sampling conditions (same kind of sterile cotton swabs, same liquid medium to help with sampling -Ringer-, and same procedure).

### §3.1 Variables studied

This study studied one dependent variable: the prevalence of *Staphylococcus aureus*, comparing it against two different independent variables: the gender of the subject and the age group of the subject. This will allow me to check for a correlation between these tw

### §3.2 Bill of materials

The materials used, as well as the quantities used, can be found in the following table. On the left, laboratory equipment and, on the right, reagents, staining agents, and consumables (none of the reagents or staining agents were assembled by me, as they were bought already-made)used:

| Qty | Material/consumable     | Qty   | Reagent                     |
|-----|-------------------------|-------|-----------------------------|
| x80 | Sterile cotton swabs    | ~30mL | Bleach                      |
| x1  | Kolle handle            | ~10mL | Methyl violet               |
| x1  | Optic microscope        | ~10mL | Iodine                      |
| x1  | Binocular magnifier     | ~10mL | Alcoholic safranin          |
| x1  | Dissection tray         | ~10mL | Methanol                    |
| x1  | Bunsen burner           | <1mL  | Ether                       |
| x1  | Lab coat                | x40   | Agar MSA plates             |
| x1  | Lab goggles             | >1L   | Ringer solution (9% saline) |
| x8  | Non-powdered gloves     |       |                             |
| x10 | Slides and slide covers |       |                             |

### §3.3 Biosecurity and risk mitigation


Staph is considered a Biosecurity Level 2 bacterium[9]. This means that it is associated with a human disease that can pose a moderate human health hazard. In a laboratory where such individuals are handled, normal lab etiquette should be followed, as well as avoiding splashes or aerosols, adhering biohazard warning signs present on all material used, and proper surfaces and material disinfection via the use of autoclave. The risks associated with this bacterium were assessed following the 2020 Biosafety Manual published by the WHO, and proper security measures were followed at all times when handling biohazardous material. No incidents occurred during the research[2].

### §3.4 Protocol followed

The protocol followed was designed based on a similar protocol used in many university laboratories[16], modified to fit the needs of this research paper. This protocol

underwent 10 different revisions. It dictates the following steps:

- 1) Set up the work area; the Bunsen burner should be turned on in such a way that it can cover an acceptable surface to work. Turn it on and try not to break the sterile field.
- 2) Prepare for the experimentation: wash your hands and put on proper PPE (mask and gloves). Wash your hands again.
- 3) Divide each Petri dish in 2 parts. Get the subject to wash their hands and observe how they do it. If they don't clean them well enough, teach them proper hand washing techniques.
- 4) Note down their information, open a sterile swab pack, dip one of the swabs in Ringer solution and swab under their nails or nose. Then, populate the dish with this sample in a zig-zag pattern for one of the halves of the dish.
- 5) Incubate for 32-48h and observe the results.
- 6) GRAM stain a sample of the plate and observe it under a microscope.



(a) Photograph of me populating a Petri dish. Source: own



(b) Photograph of me disposing of contaminated material in a biohazardous materials bag. Source: own



Figure 3.2: Panoramic photograph of the laboratory environment. Left to right:  
sampling and staining, data registry, microscopy



# 4 Physical experimentation


A scientist in his laboratory is not a mere technician: he is also a child confronting natural phenomena that impress him as though they were fairy tales.

---

Marie Curie

## §4.1 Description

This experiment is designed to detect and evaluate the prevalence of *Staphylococcus aureus* in a sample of students from our school. The process used involves extracting a sample from underneath a subject's nails by swabbing, cultivating that sample, and then observing the results of said culture to determine the presence or not of *Staphylococcus aureus* as part of the subject's resident bacterial flora. Each sampling iteration of the process took less than two minutes to complete. However, all the safety measures and actions taken need more time to be taken care of properly; as well as taking into account the fact that cultivating is not a task that can be done in just a day, often needing two to three to fully grow.



(a) Picture of the microscope view of a GRAM-stained sample. Due to the morphology and colour I suspect it's *Staphylococcus aureus*. 4000x.

(b) Picture of the microscope view of a mix between a GRAM+ and a GRAM- sample.


Figure 4.1: Source of both: own

## §4.2 Results and analysis

The results obtained can be found in the following raw data table:

| Group  | Plate | Result   | Group   | Plate | Result   |
|--------|-------|----------|---------|-------|----------|
| 1BAT A | E1    | Positive | FAM     | A5    | Positive |
| 4ESO B | B12   | Negative | FAM     | A9    | Unknown  |
| 1BAT A | C2    | Negative | FAM     | A10   | Unknown  |
| PROF   | B4    | Positive | FAM     | A11   | Negative |
| PROF   | F4    | Negative | FAM     | A12   | Positive |
| 1BAT A | E2    | Negative | PROF    | B1    | Positive |
| 1BAT A | E5    | Negative | PROF    | B3    | Positive |
| 1BAT A | E7    | Positive | 4ESO B  | B7    | Negative |
| 1BAT A | E6    | Positive | 4ESO B  | B8    | Negative |
| PROF   | C1    | Negative | 4ESO B  | B9    | Negative |
| PROF   | B2    | Negative | 4ESO D  | B10   | Negative |
| 1BAT A | E8    | Positive | 4ESO D  | B11   | Positive |
| 1BAT A | E4    | Positive | 4ESO D  | B13   | Positive |
| FAM    | D1    | Positive | 4ESO D  | B14   | Negative |
| 1BAT A | E3    | Negative | PROF    | C3    | Positive |
| PROF   | B5    | Positive | FAM     | D2    | Negative |
| FAM    | A1    | Negative | PROFJ   | F1    | Positive |
| FAM    | A2    | Positive | PROFJ   | F2    | Positive |
| FAM    | A3    | Negative | 1 Bat A | F3    | Negative |
| FAM    | A4    | Positive | 1 Bat A | E9    | Negative |
| FAM    | A6    | Negative | 1 Bat A | E10   | Negative |
| FAM    | A7    | Negative | 1BAT A  | E11   | Negative |
| FAM    | A8    | Positive | 1BAT A  | E12   | Positive |
|        |       | PROF     | A9      |       | Positive |

The data was then recounted and graphed into the following pie chart:




(a) Counts of the result cases.

(b) Pie graph of the result cases.

Figure 4.2: Data processed from results

As we can see, almost 50% of the samples taken tested positive for *Staphylococcus aureus*, compared to the expected 30%[17]. To confirm my results, I emailed two microbiology professors asking for their recent results on this kind of test, who had also found their experiments resulting in a higher prevalence than usual of this bacterium, as well as discovering cases that were previously negative but recently tested positive positive. Their results were not only confirmed by the detection of it by an MSA plate, but also by taking the morphological observation into account, both macroscopically and microscopically.



(a) *Staphylococcus aureus* as seen below the microscope. 4000x, GRAM staining  
(b) Colonies of *Staphylococcus aureus* seen under a magnifying glass, 50x, no staining

Figure 4.3: Photographies of the results, as collected from my own experimentation (own data).

There may be several reasons for the infection rate and thus natural prevalence to be increasing. One of them could be that since antibiotic abuse is growing with each passing year, the usual resident microbiota is getting killed, leaving more resources for Staph to thrive in that environment. To confirm this theory, we will look at the infection rates of a country that is facing extreme antibiotic abuse (the United States of America) and compare it to another that is controlling their antibiotics a bit better (the United Kingdom). The former have seen a 210% increase in *Staphylococcus aureus*

cases since 2006. However, superfluous antibiotic prescriptions have increased by barely 1%[18]. In the United Kingdom, they have seen a 160% increase in *Staphylococcus aureus* infections[19], and their superfluous antibiotic prescriptions have gone down by 20%. Even though this is very little data to extract conclusions from, there may be a correlation between these two factors.

Let's compare the prevalence among different groups of subjects, starting with their gender.





Figure 4.4: Data processed from results

As we can observe, there is a 10% difference in prevalence between these two genders. In my opinion, this is due to a small sample size. As we can see, the first graph, which houses the samples from subjects who identify themselves as female, has a third type of result, which the other graph, which houses the samples from subjects who self-identify as male, does not. This is simply due to a problem with the plates, however, it may affect the final result. I believe there to not be any significant difference between the two analyzed genders.



(a) Counts of the result cases in subjects younger than 20      (b) Counts of the result cases in subjects older than 40

Figure 4.5: Data processed from results

Only two age groups were studied, due to the fact that the samples fell mostly into one of these two categories. We can see that the samples from a subject older than 40 were twice as likely to test positive for *Staphylococcus aureus* than those from subjects younger than 20. This may be due to a small sample size. However, it may also be possible that the possibility of hosting this bacterium increases with age. In order to confirm this theory, more studies should be done, with a greater age gradient, as well as many more samples. It may also be the case that this change in prevalence is not caused by one single variable, but due to multiple at the same time.

# 5 Conclusions

Our reliance on the validity of a scientific conclusion depends ultimately on a judgement of coherence; and as there can exist no strict criterion for coherence, our judgement of it must always remain a qualitative, non-formal, tacit, personal judgement.

---

Michael Polanyi

## §5.1 Bibliographic conclusions

While *Staphylococcus aureus* is a dangerous bacterium given the right conditions However, most times, the immune system can get rid of it before it becomes too large of a problem. However, in some cases, when the entire body gets infected and the infection stops being localized, then that's when there is a problem. There are several strains of *Staphylococcus aureus*, classified by their resistance to antibiotics: MSSA (sensitive to methicillin), MRSA (resistant to methicillin), VISA (intermediate resistance to vancomycin) and VRSA (resistant to vancomycin). While there is no antibiotic that can deal with VRSA, an alternative in the form of a bacteriophage virus, P-68, of the order of the *Caudovirales*

## §5.2 Experimental conclusions

This study has concluded that the prevalence of *Staphylococcus aureus* in our high school is 48,8%, one and a half times the expected results. As explored previously, this could mostly be due to climate change or antibiotic abuse, however there may also be other

reasons for why this is happening. Our initial hypothesis, which was that the prevalence of epithelial *Staphylococcus aureus* in school would be at around 30% was found out to be false. Instead, the experimentation found a prevalence of the bacteria being 46,5%. This value, 1,5 times larger than the one expected. However, it probably did not come from experimental error, as the procedure was followed rigorously, and the risk of contamination was mitigated to levels with which we could confidently say that no plates were subjects of cross-contamination between batches.

The analysis of prevalence studied as a variable dependent to the subject's gender seemed to bear no different conclusions to the ones stated above. However, if studied according to the subject's age, we could see that the group comprising the samples from the older subjects were twice as likely to test positive than those from the younger subjects. Seemingly, my initial hypothesis for the second question was wrong.

### §5.3 Strengths and weaknesses

This research was not without its strengths, but neither was it without its weaknesses.

**Strengths** The protocol was adapted fairly well to the environment it was run in, and no incidents took place during the realization of the experimentation. The cost of the experimentation was relatively cheap, taking into account that reagents in microbiology can quickly get expensive. Reliability was also high, and the questions were answered, hypotheses verified and refused.

**Weaknesses** While the Agar plates used were definitely adequate for the purpose they were used for, a much more appropriate growth medium called Baird-Parker (BP) could've been used. A much more adequate and comfortable lab environment would also have been a very welcomed improvement. A much larger sample size could also have helped in giving much more accurate and precise answers to the questions asked.

## §5.4 Possible improvements

This research could've been improved by running an antibiogram on the samples, thus checking for antibiotic resistance. While this is fairly safe if adequate protections are taken, it is yet another point that could fail and result in a biosafety incident.

It could have also been improved by obtaining even a larger sample of the population, in order to get an even more significant result. The bacteria could have been sequenced, allowing us to trace back the bacterium one by one, comparing it to locations where a similar strain had been found, tracing back its evolution and possible path followed around the world.

Another interesting factor to be looked at could be the familial relationship between subjects that tested positive. It may be possible that there is some genetic character that causes members of a same family to have a predisposition of having *Staphylococcus aureus* under their nails, as compared to subjects not from the same family.

If given more time and resources, I would also have liked to look at the relationship between prevalence, age and gender with much more detail. In case I ever get to improve on my research, this will probably be the factor that I study: the relationship between the age of the subject and their likeliness to test positive to *Staphylococcus aureus*





# Works referenced

- [1] *What Is GDPR, the EU's New Data Protection Law?* <https://gdpr.eu/what-is-gdpr/>. Nov. 2018.
- [2] World Health Organization. *Laboratory Biosafety Manual*. 4th ed. Laboratory Biosafety Manual, Fourth Edition and Associated Monographs; Geneva: World Health Organization, 2020. Chap. The Portuguese version is published by PAHO: <https://iris.paho.org/handle/10665.2/54521>. ISBN: 978-92-4-001131-1.
- [3] Patrick R Murray, Ken S Rosenthal and Michael A Pfaller. *Microbiología médica*. Barcelona: Elsevier, 2013. ISBN: 978-84-9022-411-3.
- [4] *Dorlands Medical Dictionary:Disease*. [https://web.archive.org/web/20100411075617/http://www.mercksource.com/pp/us/cns/cns\\_hl\\_dorlands\\_split.jsp?pg=/ppdocs/us/common/dorlands/dorland/three/000030493.htm](https://web.archive.org/web/20100411075617/http://www.mercksource.com/pp/us/cns/cns_hl_dorlands_split.jsp?pg=/ppdocs/us/common/dorlands/dorland/three/000030493.htm). Apr. 2010.
- [5] Center for Food Safety and Applied Nutrition. ‘BAM Chapter 12: Staphylococcus Aureus’. In: *FDA* (Wed, 05/13/2020 - 17:33).
- [6] Eric F. Kong, Jennifer K. Johnson and Mary Ann Jabra-Rizk. ‘Community-Associated Methicillin-Resistant Staphylococcus Aureus: An Enemy amidst Us’. In: *PLOS Pathogens* 12.10 (Oct. 2016). Ed. by John M Leong, e1005837. ISSN: 1553-7374. DOI: [10/gdm3tb](https://doi.org/10/gdm3tb).
- [7] Cin Kong, Hui-min Neoh and Sheila Nathan. ‘Targeting Staphylococcus Aureus Toxins: A Potential Form of Anti-Virulence Therapy’. In: *Toxins* 8.3 (Mar. 2016), E72. ISSN: 2072-6651. DOI: [10/f8tnpx](https://doi.org/10/f8tnpx).
- [8] Anna Claret i Coma. ‘Resistència antibiòtica en les poblacions de lactobacils, estafilococs i entreococs aïllats de productes lleugerament fermentats.’ Projecte/Treball de Final de Carrera. Girona: Universitat de Girona, May 2004.
- [9] Gordon Y. C. Cheung, Justin S. Bae and Michael Otto. ‘Pathogenicity and Virulence of Staphylococcus Aureus’. In: *Virulence* 12.1 (Dec. 2021), pp. 547–569. ISSN: 2150-5608. DOI: [10/gm3xqz](https://doi.org/10/gm3xqz).

- [10] Kaixiang Zhou et al. ‘A Review on Nanosystems as an Effective Approach against Infections of *Staphylococcus Aureus*’. In: *International Journal of Nanomedicine* 13 (2018), pp. 7333–7347. ISSN: 1178-2013. DOI: [10/gfp2z2](https://doi.org/10/gfp2z2).
- [11] Fvasconcellos. *Skeletal Formulae of the Basic Structures of Penicillin (1) and Ceph-alo sporin (2) Antibiotics, Highlighting the Beta-Lactam Ring (Red). Created Using ACD/-ChemSketch 10.0 and Inkscape.* [https://commons.wikimedia.org/wiki/File:Beta-lactam\\_antibiotics\\_example\\_1.svg](https://commons.wikimedia.org/wiki/File:Beta-lactam_antibiotics_example_1.svg).
- [12] BartVL71. *Chemical Structure of Vancomycin.* <https://commons.wikimedia.org/wiki/-File:Vancomycin.svg>.
- [13] Anaïs Eskenazi et al. ‘Combination of Pre-Adapted Bacteriophage Therapy and Antibiotics for Treatment of Fracture-Related Infection Due to Pandrug-Resistant *Klebsiella Pneumoniae*’. In: *Nature Communications* 13.1 (Dec. 2022), p. 302. ISSN: 2041-1723. DOI: [10/hdbt](https://doi.org/10/hdbt).
- [14] Dominik Hrebík et al. ‘Structure and Genome Ejection Mechanism of *Staphylococcus Aureus* Phage P68’. In: *Science Advances* 5.10 (Oct. 2019), eaaw7414. ISSN: 2375-2548. DOI: [10/gm742z](https://doi.org/10/gm742z).
- [15] Matthew J. Kuehnert et al. ‘Prevalence of *Staphylococcus Aureus* Nasal Colonization in the United States, 2001–2002’. In: *The Journal of Infectious Diseases* 193.2 (Jan. 2006), pp. 172–179. ISSN: 0022-1899. DOI: [10/c8985p](https://doi.org/10/c8985p).
- [16] William M. O’Leary, ed. *Practical Handbook of Microbiology*. Boca Raton, Fla: CRC Press, 1989. ISBN: 978-0-8493-3704-8.
- [17] *Staphylococcus Aureus in Healthcare Settings / HAI / CDC.* <https://www.cdc.gov/hai/organisms/staph.html>. Dec. 2020.
- [18] James Baggs et al. ‘Estimating National Trends in Inpatient Antibiotic Use Among US Hospitals From 2006 to 2012’. In: *JAMA Internal Medicine* 176.11 (Nov. 2016), pp. 1639–1648. ISSN: 2168-6106. DOI: [10/ggqsvf](https://doi.org/10/ggqsvf).
- [19] Public Health England. *MSSA Bacteraemia: Annual Data.* <https://www.gov.uk/government/statistics/mssa-bacteraemia-annual-data>. Sept. 2021.

# I

## Appendix



# **Annex 1 – Informed consent given to subjects before sampling**

## **CONSENT TO BE PART OF A RESEARCH STUDY**

### **1. KEY INFORMATION ABOUT THE RESEARCHERS AND THIS STUDY**

**Study title:** A study on the affection and effects of Staphylococcus Aureus



You are invited to take part in a research study. This form contains information that will help you decide whether to join the study.

If you choose to participate, you will be asked to go to the Biology Laboratory PN22, wash profusely your hands and have a sample taken from the subungual tissue. This poses no risk andd will take around 2 to 7 minutes. The results will be delivered to you in 24-48 hours, in paper form. There are no other direct benefits.

Taking part in this research project is voluntary. You do not have to participate and you can stop at any time. Please take time to read this entire form and ask questions before deciding whether to take part in this research project.

### **2. PURPOSE OF THIS STUDY**

The purpose of this study is to evaluate the percentage of students whose reseident bacterioflora include *Staphylococcus aureus*, as well as a genomic analysis of a random one of the positive samples.

We may use the subungual tissue collected for this study for whole bacterial genome sequencing which involves mapping all of the bacteria DNA to screen for MRSA and MSSA.

### **3. WHO CAN PARTICIPATE IN THE STUDY**

**3.1 Who can take part in this study?** There is no application criteria.

**3.2 How many people are expected to take part in this study?** About 40-60 people are expected to take part in this study.

### **4. INFORMATION ABOUT STUDY PARTICIPATION**

#### **4.1 What will happen to me in this study?**

- You will be called to the Biology Laboratory
- You will be asked to follow simple instructions to wash your hands
- A sample from below your nails will be taken and cultured
- If positive, your sample may be chosen for sequencing.
- You will be given all your results 24-48h after sampling in paper form.

The process can be found in detail at [dx.doi.org/10.17504/protocols.io.81wgb6pk1lpk/v6](https://dx.doi.org/10.17504/protocols.io.81wgb6pk1lpk/v6)

**4.2 How much of my time will be needed to take part in this study?** This will take one day, 5-10 minutes total maximum.

**4.3 If I decide not to take part in this study, what other options do I have?**  
Leave and not get your results.

## **5. INFORMATION ABOUT STUDY RISKS AND BENEFITS**

**5.1 What risks will I face by taking part in the study? What will the researchers do to protect me against these risks?**

There are no known risks.

**5.2 How could I benefit if I take part in this study? How could others benefit?**

You may not receive any personal benefits from being in this study. However, others may benefit from the knowledge gained from this study. You will receive your results.

**5.2.1 Will the researchers provide information to me about what they learn from analyzing my [type of biospecimen]?** We may learn things about your health as part of the research. If this happens, this information will be provided to you. [Insert a description of the types of research results that may be returned, under what circumstances participants will be provided research results, and how participants will be notified.] You may need to meet with professionals with expertise to help you learn more about your research results. The study team/study will not cover the costs of any follow-up consultations or actions.

**5.3 Will the researchers tell me if they learn of new information that could change my willingness to stay in this study?** Yes, the researchers will tell you if they learn of important new information that may change your willingness to stay in this study.

## **6. ENDING THE STUDY**

**6.1 If I want to stop participating in the study, what should I do?**

You are free to leave the study at any time. If you leave the study before it is finished, there will be no penalty to you. You will not lose any benefits to which you may otherwise be entitled. If you decide to leave the study before it is finished, please tell one of the persons listed in Section 9 "Contact Information". If you choose to tell the researchers why you are leaving the study, your reasons may be kept as part of the study record. The researchers will keep the information [and type of biospecimen] collected about you for the research unless you ask us to remove the information from our records and destroy the [type of biospecimen]. If the researchers have already used your information in a research analysis, it will not be possible to remove your information.

## **7. FINANCIAL INFORMATION**

No money will be transferred.

## **8. PROTECTING AND SHARING RESEARCH INFORMATION [AND BIOSPECIMENS]**

**8.1 How will the researchers protect my information? Following GDPR regulations.**

**8.2 Who will have access to my research records?**

There are reasons why information about you may be used or seen by the researchers or others during or after this study. Examples include:

- University, government officials, study sponsors or funders, auditors, and/or the Institutional Review Board (IRB) may need the information to make sure that the study is done in a safe and proper manner.

**8.3 What will happen to the information and/or biospecimens collected in this study?**

We will keep the information and/or biospecimens we collect about you during the research, [including information we learn from analyzing your sample, for future research projects and for study recordkeeping. Your name and other information that can directly identify you will be stored securely and separately from the research information we collected from you..

The results of this study could be published in an article or presentation, but will not include any information that would let others know who you are.

**8.4 Will my information and/or biospecimens be used for future research or shared with others?**

We may use or share your research information and/or biospecimen for future research studies. If we share your information and/or biospecimen with other researchers it will be de-identified, which means that it will not contain your name or other information that can directly identify you. This research may be similar to this study or completely different. We will not ask for your additional informed consent for these studies.

We would like to share your identifiable information or biospecimen with other researchers for future research. We will ask for your consent to do so at the end of this consent document. You can be a part of this current research project without agreeing to this future use of your identifiable information or biospecimen.

## 9. CONTACT INFORMATION

### Who can I contact about this study?

Please contact the researchers listed below to:

- Obtain more information about the study
- Ask a question about the study procedures
- Report an illness, injury, or other problem (you may also need to tell your regular doctors)
- Leave the study before it is finished
- Express a concern about the study





## **Annex 2 – GDPR notice given to subjects before sampling**

## **GDPR NOTICE**

You are receiving this notice in connection with your participation in the following research study:

**Title of Study:** A study on the affectation and effects of Staphylococcus Aureus

**Principal Investigator:** [REDACTED]

The above-named research study involves the collection of *sensitive personal data* that can identify you. The General Data Protection Regulation ("GDPR") requires researchers to provide this notice to you when we collect and use research data about people located within the European Union (EU) or the European Economic Area (EEA). This notice outlines what personal data we will collect, how we intend to use and protect this information, and your rights with respect to your personal data for purposes of GDPR.

NOTE: The GDPR may apply to *personal data* that you provide while physically located in the EU/EEA. It does not apply to information provided while located outside of the EU/EEA (e.g., while in the United States). GDPR data protection requirements do not apply to your personal data that is rendered anonymous such that you are not identifiable or can no longer be identified.

### **Personal data – what we will collect**

As part of this research study, we will create and obtain information related to your participation in the study from you so we can conduct this research. Research study data will include: contact information and physiological data that arises from the test, which will include the presence or not of bacteria and the concentration of it.

### **How we will use your Personal Data**

The personal data you provide will be used for the following purposes:

- To fulfill study objectives as described within the Study Informed Consent Form
- To provide study compensation and complying with compensation-related reporting requirements
- To comply with legal and regulatory requirements, including requirements to share data with regulatory agencies overseeing the research
- To confirm proper conduct of the study and research integrity

Your personal data may be transferred to the United States in condition of storage. The United States does not have the same laws to protect your personal data as in the EU/EEA. However, we are committed to protecting the confidentiality of the personal data you give us. The *Study Informed Consent form* further describes the protections in place to protect the confidentiality of your personal data. Transfer and use of your personal data is on the basis of your consent.

### **Retention of your personal data**

We may retain your personal data for as long as necessary to fulfill the objectives of

the research and to ensure the integrity of the research. We will delete your personal data when it is no longer needed for the study or if you withdraw your consent provided such deletion does not render impossible or seriously impair the achievement of the objectives of the research project. However, your information will be retained as necessary to comply with legal or regulatory requirements. Your data will be anonymized as soon as the results of your test have been sent to you by using a unique randomized identifier. No non-anonymized data will be used for future studies.

### **Your rights with respect to your personal data**

If you participate in this study within the EU/EEA the GDPR affords you certain rights with respect to your personal data, including the right to:

- Access, correct, withdraw, or delete your personal data; however, the research team may need to keep your personal data as long as it is necessary to achieve the purpose of this research;
- Restrict the types of activities the research team can do with your personal data;
- Object to using your personal data for specific types of activities; or
- Withdraw your consent to use your personal data for the purposes outlined in the *Study Informed Consent form* and in this document. (However, this withdrawal will only apply to new personal data not yet collected or created. Personal data already collected or created may continue to be used as outlined in the *Study Informed Consent form* and this document.)

To exercise your rights, please use the contact information below to submit a request. When you submit a request, please indicate your name, the name of this project, your reasons for making the request, if necessary, and other details you think will be useful for us to comply with your request.

### **Where to address your questions or concerns about your personal data**

If you want to make a request relating to the rights listed above or if you have any concerns about how your personal data is being handled, please contact:



### **Your Consent**

**Your consent is entirely voluntary, but declining to provide consent may impede your ability to participate in this research project.**

By clicking below, you indicate that you have read and understood how your personal data will be processed, your related rights, and that you consent to the processing of your data as provided in this document. In addition, you acknowledge

that this information was explained to you, your questions have been answered, and that you wish to continue participating in the study. If any new questions arise, you can contact the research team using the information provided above.

You may print a copy of this form for your files.

Name:

I acknowledge that this new information was explained to me, my questions have been answered to my satisfaction, and I wish to participate in this study.

## **Annex 3 – Bibliography consulted (but not referenced)**

- [1] G. Verger, Ll Carbó and Fundació Dr Antoni Esteve. *Problemas que se plantean en el tratamiento de infecciones graves por S. Aureus* / [editores]: G. Verger, Ll. Carbó. Barcelona, 1986.
- [2] William M. O'Leary, ed. *Practical Handbook of Microbiology*. Boca Raton, Fla: CRC Press, 1989. ISBN: 978-0-8493-3704-8.
- [3] Alan J. Lacey, ed. *Light Microscopy in Biology: A Practical Approach*. 2. ed. The Practical Approach Series 195. Oxford: Oxford Univ. Press, 1999. ISBN: 978-0-19-963669-3 978-0-19-963670-9.
- [4] Anthony J. F. Griffiths, ed. *Modern Genetic Analysis*. 3rd print. New York, NY: W. H. Freeman, 2000. ISBN: 978-0-7167-3597-7 978-0-7167-3118-4 978-0-7167-3347-8.
- [5] Anna Claret i Coma. ‘Resistència antibòtica en les poblacions de lactobacils, estafilococs i entreococs aïllats de productes lleugerament fermentats.’ Projecte/Treball de Final de Carrera. Girona: Universitat de Girona, May 2004.
- [6] David W. Mount. *Bioinformatics: Sequence and Genome Analysis*. 2nd ed. Cold Spring Harbor, N.Y: Cold Spring Harbor Laboratory Press, 2004. ISBN: 978-0-87969-687-0 978-0-87969-712-9.
- [7] Matthew J. Kuehnert et al. ‘Prevalence of Staphylococcus Aureus Nasal Colonization in the United States, 2001-2002’. In: *The Journal of Infectious Diseases* 193.2 (Jan. 2006), pp. 172–179. ISSN: 0022-1899. DOI: [10/c8985p](https://doi.org/10/c8985p).
- [8] Fvasconcellos WikMedia user. *File:Beta-lactam Antibiotics Example 1.Svg - Wikipedia*. [https://commons.wikimedia.org/wiki/File:Beta-lactam\\_antibiotics\\_example\\_1.svg](https://commons.wikimedia.org/wiki/File:Beta-lactam_antibiotics_example_1.svg). Oct. 2007.
- [9] BAIRD-PARKER Agar (*Staphylococcus Selective Agar Base Acc. to BAIRD-PARKER*). [https://web.archive.org/web/20080501041929/http://www.emdchemicals.com/analytics/Micro\\_Manual/TEDIS-data/prods/1\\_05406\\_0500.html](https://web.archive.org/web/20080501041929/http://www.emdchemicals.com/analytics/Micro_Manual/TEDIS-data/prods/1_05406_0500.html). May 2008.
- [10] BartVL71 WikMedia user. *File:Vancomycin.Svg - Wikipedia*. <https://commons.wikimedia.org/wiki/File:Vancomycin.svg>. Oct. 2008.
- [11] Dong Xu and Yang Zhang. ‘Generating Triangulated Macromolecular Surfaces by Euclidean Distance Transform’. In: *PLoS ONE* 4.12 (Dec. 2009). Ed. by Markus J. Buehler, e8140. ISSN: 1932-6203. DOI: [10/d6tf9f](https://doi.org/10/d6tf9f).
- [12] Dorlands Medical Dictionary:Disease. [https://web.archive.org/web/20100411075617/http://www.mercksource.com/pp/us/cns/cns\\_hl\\_dorlands\\_split.jsp?pg=/ppdocs/us/common/dorlands/dorland/three/000030493.htm](https://web.archive.org/web/20100411075617/http://www.mercksource.com/pp/us/cns/cns_hl_dorlands_split.jsp?pg=/ppdocs/us/common/dorlands/dorland/three/000030493.htm). Apr. 2010.
- [13] Carlos Gamazo, Ramón Díaz and Ignacio López-Goñi. *Manual práctico de microbiología*. Barcelona: Elsevier Masson, 2010. ISBN: 978-84-458-1519-9.
- [14] Global Warming. <https://earthobservatory.nasa.gov/features/GlobalWarming/page2.php>. Text.Article. June 2010.

- [15] John T. Moore and Richard Langley. *Biochemistry for Dummies*. 2nd ed. –For Dummies. Hoboken, NJ: Wiley Pub, 2011. ISBN: 978-1-118-02174-3.
- [16] Gloria Inés Puerta Quintero. ‘Fundamentos Del Proceso de Fermentación En El Beneficio Del Café’. In: *Avances técnicos Cenicafe* (2012). ISSN: 0120-0178.
- [17] Patrick R Murray, Ken S Rosenthal and Michael A Pfaller. *Microbiología médica*. Barcelona: Elsevier, 2013. ISBN: 978-84-9022-411-3.
- [18] James Baggs et al. ‘Estimating National Trends in Inpatient Antibiotic Use Among US Hospitals From 2006 to 2012’. In: *JAMA Internal Medicine* 176.11 (Nov. 2016), pp. 1639–1648. ISSN: 2168-6106. DOI: [10/ggqsvf](https://doi.org/10/ggqsvf).
- [19] NASA’s GMS. *GMS: Annual Global Temperature, 1880-2015*. <https://svs.gsfc.nasa.gov/12133>. Jan. 2016.
- [20] Cin Kong, Hui-min Neoh and Sheila Nathan. ‘Targeting Staphylococcus Aureus Toxins: A Potential Form of Anti-Virulence Therapy’. In: *Toxins* 8.3 (Mar. 2016), E72. ISSN: 2072-6651. DOI: [10/f8tnpx](https://doi.org/10/f8tnpx).
- [21] Eric F. Kong, Jennifer K. Johnson and Mary Ann Jabra-Rizk. ‘Community-Associated Methicillin-Resistant Staphylococcus Aureus: An Enemy amidst Us’. In: *PLOS Pathogens* 12.10 (Oct. 2016). Ed. by John M Leong, e1005837. ISSN: 1553-7374. DOI: [10/gdm3tb](https://doi.org/10/gdm3tb).
- [22] Tzu-Sen Yang et al. ‘Disinfection Effects of Undoped and Silver-Doped Ceria Powders of Nanometer Crystallite Size’. In: *International Journal of Nanomedicine* 11 (June 2016), p. 2531. DOI: [10/f8p99f](https://doi.org/10/f8p99f).
- [23] Professor Dave Explains. *Viruses: Molecular Hijackers*. Oct. 2017.
- [24] Xiaopeng Zhang, Xiaomei Hu and Xiancai Rao. ‘Apoptosis Induced by Staphylococcus Aureus Toxins’. In: *Microbiological Research* 205 (Dec. 2017), pp. 19–24. ISSN: 1618-0623. DOI: [10/gcf5pm](https://doi.org/10/gcf5pm).
- [25] SAHIL BATRA. *Biochemical Tests for Staphylococcus Aureus / Bacteriology Notes*. <https://paramedicsworld.com/staphylococcus-aureus/biochemical-tests-staphylococcus-aureus/medical-paramedical-studynotes>. Sept. 2018.
- [26] SAHIL BATRA. *Biochemical Tests For Streptococcus Pneumoniae / Bacteriology Notes*. <https://paramedicsworld.com/streptococcus-pneumoniae-pneumococcus/biochemical-tests-for-streptococcus-pneumoniae/medical-paramedical-studynotes>. Sept. 2018.
- [27] TED. *How a Long-Forgotten Virus Could Help Us Solve the Antibiotics Crisis / Alexander Belcredi*. 2018.
- [28] *What Is GDPR, the EU’s New Data Protection Law?* <https://gdpr.eu/what-is-gdpr/>. Nov. 2018.
- [29] Kaixiang Zhou et al. ‘A Review on Nanosystems as an Effective Approach against Infections of Staphylococcus Aureus’. In: *International Journal of Nanomedicine* 13 (2018), pp. 7333–7347. ISSN: 1178-2013. DOI: [10/gfp2z2](https://doi.org/10/gfp2z2).

- [30] Shayla Hesse and Sankar Adhya. ‘Phage Therapy in the Twenty-First Century: Facing the Decline of the Antibiotic Era; Is It Finally Time for the Age of the Phage?’ In: *Annual Review of Microbiology* 73.1 (Sept. 2019), pp. 155–174. ISSN: 0066-4227, 1545-3251. DOI: [10/gqwcss](https://doi.org/10/gqwcss).
- [31] Dominik Hrebík et al. ‘Structure and Genome Ejection Mechanism of *Staphylococcus Aureus* Phage P68’. In: *Science Advances* 5.10 (Oct. 2019), eaaw7414. ISSN: 2375-2548. DOI: [10/gm742z](https://doi.org/10/gm742z).
- [32] Dominik Hrebík et al. ‘Structure and Genome Ejection Mechanism of *Staphylococcus Aureus* Phage P68’. In: *Science Advances* 5.10 (Oct. 2019), eaaw7414. ISSN: 2375-2548. DOI: [10/gm742z](https://doi.org/10/gm742z).
- [33] Aleksandra Petrovic Fabijan et al. ‘Safety of Bacteriophage Therapy in Severe *Staphylococcus Aureus* Infection’. In: *Nature Microbiology* 5.3 (Mar. 2020), pp. 465–472. ISSN: 2058-5276. DOI: [10/gqbj7f](https://doi.org/10/gqbj7f).
- [34] *Staphylococcus Aureus in Healthcare Settings | HAI | CDC*. <https://www.cdc.gov/hai/organisms/staph.html>. Dec. 2020.
- [35] World Health Organization. *Laboratory Biosafety Manual*. 4th ed. Laboratory Biosafety Manual, Fourth Edition and Associated Monographs; Geneva: World Health Organization, 2020. Chap. The Portuguese version is published by PAHO: <https://iris.paho.org/handle/10665.2/54521>. ISBN: 978-92-4-001131-1.
- [36] 74 Asamblea Mundial de la Salud. *Mejora de la bioseguridad en los laboratorios*. Tech. rep. Ginebra: Organización Mundial de la Salud, 2021. Chap. 7 p.
- [37] 74 Assemblée mondiale de la Santé. *Renforcement de la sécurité biologique en laboratoire*. Tech. rep. Genève: Organisation mondiale de la Santé, 2021. Chap. 7 p.
- [38] Gordon Y. C. Cheung, Justin S. Bae and Michael Otto. ‘Pathogenicity and Virulence of *Staphylococcus Aureus*’. In: *Virulence* 12.1 (Dec. 2021), pp. 547–569. ISSN: 2150-5608. DOI: [10/gm3xqz](https://doi.org/10/gm3xqz).
- [39] Public Health England. *MSSA Bacteraemia: Annual Data*. <https://www.gov.uk/government/statistics/mssa-bacteraemia-annual-data>. Sept. 2021.
- [40] John Jumper et al. ‘Highly Accurate Protein Structure Prediction with AlphaFold’. In: *Nature* 596.7873 (2021), pp. 583–589. DOI: [10/gk7nfp](https://doi.org/10/gk7nfp).
- [41] Organisation mondiale de la Santé. *Renforcer la résilience du système de santé pour instaurer la couverture sanitaire universelle et la sécurité sanitaire pendant et après la COVID-19 : exposé de la position de l'OMS*. Tech. rep. Genève: Organisation mondiale de la Santé, 2021. Chap. xii, 39 p.
- [42] 74 World Health Assembly. *Enhancement of Laboratory Biosafety*. Tech. rep. Geneva: World Health Organization, 2021. Chap. 6 p.

- [43] World Health Organization. *Guidance Framework for Testing Genetically Modified Mosquitoes*. 2nd ed. Geneva: World Health Organization, 2021. Chap. xxvi, 165 p. ISBN: 978-92-4-002523-3.
- [44] World Health Organization = Organisation mondiale de la Santé. ‘Case Report of Laboratory-Acquired Vaccinia Virus Infection in India Cas d’infection En Laboratoire Par Le Virus de La Vaccine En Inde’. In: *Weekly Epidemiological Record = Relevé épidémiologique hebdomadaire* 96.05/06 (Feb. 2021), pp. 33–39.
- [45] World Health Organization = Organisation mondiale de la Santé. ‘Weekly Epidemiological Record, 2020, Vol. 96, 05/06 [Full Issue]’. In: *Weekly Epidemiological Record = Relevé épidémiologique hebdomadaire* 96.05/06 (Feb. 2021), pp. 33–44.
- [46] Anaïs Eskenazi et al. ‘Combination of Pre-Adapted Bacteriophage Therapy and Antibiotics for Treatment of Fracture-Related Infection Due to Pandrug-Resistant Klebsiella Pneumoniae’. In: *Nature Communications* 13.1 (Dec. 2022), p. 302. ISSN: 2041-1723. DOI: [10/hdbt](https://doi.org/10/hdbt).
- [47] *Fig. 2. Effect of Temperature on the Growth of S. Aureus*. [https://www.researchgate.net/figure/Effect-of-temperature-on-the-growth-of-S-aureus\\_fig6\\_266137314](https://www.researchgate.net/figure/Effect-of-temperature-on-the-growth-of-S-aureus_fig6_266137314). Sept. 2022.
- [48] M.R. KFL082 and Olga Sánchez. ‘Staphilococcus Aureus Sampling V10’. In: *protocols.io* 8 (Sept. 2022). DOI: [10/gqwcst](https://doi.org/10/gqwcst).
- [49] Organisation mondiale de la Santé. *Analyses en laboratoire pour la détection du virus de la variole du singe (orthopoxvirose simienne) : orientations provisoires*, 23 mai 2022. Tech. rep. Genève: Organisation mondiale de la Santé, 2022. Chap. 7 p.
- [50] Organización Mundial de la Salud. *Pruebas de laboratorio para el virus de la viruela símica: orientaciones provisionales*, 23 de mayo de 2022. Tech. rep. Ginebra: Organización Mundial de la Salud, 2022. Chap. 7 p.
- [51] *Plasma Membrane (Cell Membrane)*. <https://www.genome.gov/genetics-glossary/Plasma-Membrane>. Sept. 2022.
- [52] World Health Organization. *Global Guidance Framework for the Responsible Use of the Life Sciences: Mitigating Biorisks and Governing Dual-Use Research*. Geneva: World Health Organization, 2022. ISBN: 978-92-4-005610-7.
- [53] World Health Organization. *Joint External Evaluation Tool: International Health Regulations (2005)*. 3rd ed. Geneva: World Health Organization, 2022. Chap. v, 132 p. ISBN: 978-92-4-005198-0.
- [54] World Health Organization. *Laboratory Testing for the Monkeypox Virus: Interim Guidance*, 23 May 2022. Tech. rep. Geneva: World Health Organization, 2022. Chap. 6 p.
- [55] World Health Organization. Regional Office for South-East Asia. *Programme Budget Performance Assessment: 20202021*. Tech. rep. New Delhi: World Health Organization. Regional Office for South-East Asia, 2022.

- [56] BartVL71. *Chemical Structure of Vancomycin*. <https://commons.wikimedia.org/wiki/-File:Vancomycin.svg>.
- [57] Fvasconcellos. *Skeletal Formulae of the Basic Structures of Penicillin (1) and Cephalosporin (2) Antibiotics, Highlighting the Beta-Lactam Ring (Red). Created Using ACD/ChemSketch 10.0 and Inkscape*. [https://commons.wikimedia.org/wiki/File:Beta-lactam\\_antibiotics\\_example\\_1.svg](https://commons.wikimedia.org/wiki/File:Beta-lactam_antibiotics_example_1.svg).
- [58] *Definition of PREVALENCE*. <https://www.merriam-webster.com/dictionary/prevalence>. undefined.
- [59] *Diccionari Enciclopèdic de Medicina (DEMCAT). Versió de Treball / TERMCAT*. <https://www.termcat.cat/ca/diccionaris-en-linia/183. ->.
- [60] *Google Colaboratory - Alpha Fold 2*. <https://colab.research.google.com/github/sokrypton/-ColabFold/blob/main/AlphaFold2.ipynb#scrollTo=kOblAo-xetgx>. -.
- [61] *Immunology - YouTube*. <https://www.youtube.com/>. multiple.
- [62] *Interaction between Streptococcus Pneumoniae and Staphylococcus Aureus Generates ·OH Radicals That Rapidly Kill Staphylococcus Aureus Strains*. <https://journals.asm.org/doi/e-pub/10.1128/JB.00474-19. ->. DOI: [10.1128/JB.00474-19](https://doi.org/10.1128/JB.00474-19).
- [63] *Laboratory Notebook · Benchling*. <https://benchling.com/s/etr-sGhwNi3thI69pBb3Gw1g/edit?m=slm-1ZNe5iE4Txvx812cVgxw>. -.
- [64] *Microbiology/Infectious Diseases - YouTube*. <https://www.youtube.com/playlist?list=PLYbg94GvOJ9HH55nc->.
- [65] Center for Food Safety and Applied Nutrition. ‘BAM Chapter 12: Staphylococcus Aureus’. In: FDA (Wed, 05/13/2020 - 17:33).
- [66] *Promoting Biosecurity by Professionalizing Biosecurity*. [https://www.science.org/doi/epdf/10.1126/science.aba0376?adobe\\_mc=MCMID%3D34422769753108397802497074084661275174%7CM-CORGID%3D242B6472541199F70A4C98A6%2540AdobeOrg%7CTS%3D1639589098. -](https://www.science.org/doi/epdf/10.1126/science.aba0376?adobe_mc=MCMID%3D34422769753108397802497074084661275174%7CM-CORGID%3D242B6472541199F70A4C98A6%2540AdobeOrg%7CTS%3D1639589098. -). DOI: [10.1126/science.aba0376](https://doi.org/10.1126/science.aba0376).
- [67] *Staphylococcus Aureus Toxins | Elsevier Enhanced Reader*. <https://reader.elsevier.com/reader/sd/pii/S1369527413002191?token=A32ABB40B09CB72E7261B7B00541C8BF22151150B0A7472A8940E&ginRegion=eu-west-1&originCreation=20211215173133>. multiple. DOI: [10.1016/j.mib.2013.11.004](https://doi.org/10.1016/j.mib.2013.11.004).